Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer

Cancer Prevention Research

Volumn 4, Issue 10, 2011, Pages 1536-1545

  Uddin, Md Jashim ^a   Crews, Brenda C ^a   Ghebreselasie, Kebreab ^a   Huda, Imran ^a   Kingsley, Philip J ^a   Ansari, Mohammad Sib ^b   Tantawy, Mohammed N ^b   Reese, Jeffery ^c   Marnett, Lawrence J ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; CELECOXIB; CELECOXIB DERIVATIVE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUORINE 18; INDOMETACIN; INDOMETACIN DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME STRUCTURE; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MOLECULAR IMAGING; MOUSE; NEOPLASM; NONHUMAN; PAW EDEMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; RAT; TUMOR XENOGRAFT;

ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HALOGENATION; HUMANS; INDOMETHACIN; INFLAMMATION; MALE; MICE; MICE, NUDE; MOLECULAR IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 80053905361     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0120     Document Type: Article

References (25)

1. Baker M. Whole-animal imaging: the whole picture. Nature 2010;463:977-80.
2. Giepmans BNG, Adams SR, Ellisman MH, Tsien RY. The fluorescent toolbox for assessing protein location and function. Science 2006;312:217-24.
3. Neri D, Carnemolla B, Nissim A, Leprini A, Querzè G, Balza E, et al. Targeting by affinity-matured recombinent antibody fragments of an angiogenesis-associated fibronectin isoform. Nat Biotechnol 1997;15:1271-5. (Pubitemid 27465138)
4. Becker A, Riefke B, Ebert B, Sukowski U, Rinneberg H, Semmler W, et al. Macromolecular contrast agents for optical imaging of tumors: comparison of indotricarbocyanine-labeled human serum albumin and transferin. Photochem Photobiol 2000;72:234-41.
5. Ntziachristos V, Tung C-H, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protesase activity in vivo. Nat Med 2002;8;757-60. (Pubitemid 34778731)
6. Blum G, Mullins SR, Keren K, Fonovic M, Jedeszko C, Rice MJ, et al. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat Chem Biol 2005;1:203-9.
7. Achilefu S, Bloch S, Markiewicz MA, Zhong T, Ye Y, DorshowRB, et al. Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression. Proc Natl Acad Sci U S A 2005;102:7976-81. (Pubitemid 40781048)
8. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Can Inst 1998;90:1529-36.
9. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-8.
10. Kalgutkar AS, Marnett AB, Crews BC, Remmel RP, Marnett LJ. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem 2000;43:2860-70. (Pubitemid 30599644)
11. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-75.
12. Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, et al. Selective visualization of cyclooxygenase-2 in inflammation and cancer withtargetedimaging agents.CancerRes 2010;70:3618-27.
13. 123I]- Celecoxib analogs as SPECT tracer of cyclooxygenase-2 (COX-2) in inflammation. ACS Med Chem Lett 2011;2:160-4.
14. 18F]-4-[5-(4-methylphenyl)- 3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide as a PET imaging probe for COX-2 expression. Bioorg Med Chem 2007;15:1802-7.
15. 18F-desbromo-DuP-697 as a PET tracer for cyclo-oxygenase-2 expression. J Nucl Med 2003;44:1700-6.
16. 18F-labeled COX-1 and COX-2 inhibitors. J Nucl Med 2002;43:117-24.
17. Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiol 1993;79:795-807. (Pubitemid 23296712)
18. Hart FD, Boardman PL. Indomethacin: a new non-steroid anti-inflammatory agent. Br Med J 1963;5363:965-70.
19. Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, et al. The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)- 3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg Med Chem Lett 1999;9:1773-8. (Pubitemid 29287387)
20. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, et al. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal anti-inflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A 2000;97:925-30. (Pubitemid 30070411)
21. Kalgutkar AS, Kozak KR, Crews BC, Hochgesang GP, Marnett LJ. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem 1998;41:4800-18. (Pubitemid 28530456)
22. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-9.
23. Loening AM, Gambhir SS. AMIDE: a free software tool for multi-modality medical image analysis. Mol Imaging 2003;2:131-37.
24. Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc Soc Exp Biol Med 1962;111:544-7.
25. Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, et al. Eicosanoid modulation in advanced lung cancer: cycloxygenase-2 expression is a positive predictive factor, for celecoxib + chemotherapy-Cancer and Leukemia Group B trial 30203. J Clin Oncol 2008;26,848-55. (Pubitemid 351398075)